Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics (NYSE: DGX) announced its participation at the Jefferies Healthcare Conference, scheduled for June 10, 2022, at 11:00 a.m. ET. CEO Steve Rusckowski and CEO-elect Jim Davis will outline the company's vision, goals, and capital allocation strategies. The event will be webcast live and archived for viewing on their investor relations page within 24 hours. Quest Diagnostics provides diagnostic insights to improve health outcomes for over one-third of adult Americans, maintaining a significant presence in the healthcare sector.

Quest Diagnostics (DGX) announced that its Senior VP and Chief Human Resources Officer, Cecilia McKenney, received the "CHRO Lifetime Achievement Award" from SharedXpertise Media. Recognized for her leadership during the COVID-19 pandemic, McKenney has championed initiatives promoting employee well-being and inclusion since joining the company in 2018. CEO Steve Rusckowski praised her empathetic leadership style, highlighting her positive impact on the organization. The award celebrates CHROs who drive innovation and excellence in employee engagement and retention, further emphasizing the importance of strong HR leadership in business growth.

Quest Diagnostics (NYSE: DGX) declared a quarterly cash dividend of $0.66 per share, scheduled for payment on July 20, 2022. Shareholders of record as of July 6, 2022 will receive this dividend. This distribution reflects the company’s commitment to returning value to its investors.

Quest Diagnostics is a leader in diagnostic services, serving one in three adult Americans and half of U.S. physicians and hospitals. Its insights aim to improve health outcomes and healthcare management.

Quest Diagnostics (NYSE: DGX) will present at the UBS 2022 Global Healthcare Conference on May 24, 2022, at 3:30 p.m. ET. CEO Steve Rusckowski and CEO-elect Jim Davis will discuss the company's vision and capital strategies. The event will be available via live webcast on the company's investor relations page and archived for later viewing until June 23, 2022. Quest Diagnostics is a leader in diagnostic information services, supporting health improvements for a significant portion of the U.S. population.

Quest Diagnostics has introduced a blood test, QUEST AD-Detect™, to assess the risk of Alzheimer's Disease (AD), amidst rising optimism among physicians and patients for advancements in AD diagnostics and treatment. A recent survey showed 66% of physicians anticipate groundbreaking therapies, with 84% believing early risk testing will enhance disease management. However, cost concerns may hinder widespread adoption. Despite this, 87% of physicians think the blood test will become a standard practice, highlighting an evolving landscape in AD healthcare.

Quest Diagnostics (DGX) reported Q1 2022 revenues of $2.61 billion, a 4.0% decline compared to 2021. Reported diluted EPS was $2.92, down 15.6%, while adjusted diluted EPS was $3.22, a drop of 14.4%. Base business revenues rose 6.3% to $2.01 billion. Despite COVID-19 testing revenue decreasing 27.6% to $599 million, full-year guidance was raised. The new diluted EPS guidance ranges from $7.88 to $8.38, with adjusted EPS expected between $9.00 and $9.50.

Quest Diagnostics (NYSE: DGX) announced key organizational changes to enhance operational efficiency and growth. Catherine T. Doherty has been appointed Senior VP for Regional Businesses, while Carrie E. Eglinton Manner takes on Senior VP for Advanced & General Diagnostics Clinical Solutions. Patrick T. Plewman is now Senior VP for Diagnostic Services, and Mark E. Delaney joins as Chief Commercial Officer. Additionally, Richard F. Adams steps in as VP and GM for Consumer Initiated Testing. The company aims to improve strategy execution and strengthen its leadership team.

Quest Diagnostics has announced a collaboration with IRIS to offer diabetic retinal imaging services at its patient service centers across the United States. This initiative aims to enhance access to screenings for diabetic retinopathy, a leading cause of blindness, particularly for patients identified as high-risk by participating health plans. The collaboration is designed to improve screening rates and health outcomes by enabling early detection and treatment. Training for Quest personnel will ensure images are sent to licensed ophthalmologists for evaluation.